Keyphrases:

Tolmar
Galderma
0.3
acne
%
topical
medication
ingredient
S.N.C.
1034__BIG_TOKEN
====================================
top sentences:

BACKGROUND This Hatch-Waxman case is based on Tolmar 's filing of an Abbreviated New Drug Application ( `` ANDA '' ) seeking approval to market a generic version of Differin ( r ) Gel , 0.3 % , which is a topical medication containing 0.3 % by weight adapalene approved for the treatment of acne .
2.669580
On January 21 , 2010 , Galderma sued Tolmar in the United_States_District_Court for the District of Delaware , alleging that Tolmar 's ANDA product infringed certain claims of the BIG_TOKEN__¡¬377_patent__BIG_TOKEN .
2.642735
Galderma subsequently filed amended complaints alleging infringement of each of the asserted patents .
2.463232
The Court of Appeals , Prost , Circuit_Judge , held that the patents , which taught use of active ingredient at 0.3 % concentration , were invalid as obvious in light of prior art that disclosed preferred range of 0.01 % -1 % for that ingredient , with same inactive ingredients .
1.964109
Synopsis Background : Patentee brought infringement action against generic drug manufacturer , alleging infringement of its patents for a topical acne medication .
1.816868
